|Bid||38.70 x 1100|
|Ask||39.50 x 2200|
|Day's Range||38.43 - 39.79|
|52 Week Range||9.53 - 70.29|
|Beta (5Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 28, 2022 - Mar. 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.50|
Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, in combination with a rituximab or cyclophosphamide regimen, indicated for the treatment of adult patients with severe, active g